Nicholas M Smith

List of Publications by Year
in descending order

12	184	1307594 7	1281871 11
papers	citations	h-index	g-index

12	12	12	321
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	60
2	Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infectious Diseases and Therapy, 2015, 4, 391-415.	4.0	45
3	Rational Combinations of Polymyxins with Other Antibiotics. Advances in Experimental Medicine and Biology, 2019, 1145, 251-288.	1.6	21
4	Pharmacodynamics of dose-escalated â€˜front-loadingâ€™ polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli. Journal of Antimicrobial Chemotherapy, 2017, 72, 2297-2303.	3.0	14
5	Bacterial brothers in arms: cooperation of Staphylococcus aureus and Pseudomonas aeruginosa during antimicrobial exposure. Journal of Antimicrobial Chemotherapy, 2019, 74, 2657-2665.	3.0	12
6	Interaction of Staphylococcus aureus and Acinetobacter baumannii during In Vitro Î²-Lactam Exposure. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	10
7	Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 1582-1589.	1.6	9
8	Combatting the Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision. International Journal of Antimicrobial Agents, 2021, 57, 106269.	2.5	8
9	The Development of an In Vitro Assay for the Prospective Determination of Aspirin Sensitivity. Journal of Clinical Pharmacology, 2018, 58, 1150-1156.	2.0	2
10	Openâ€Source Maximum a Posteriori â€Bayesian Dosing AdDS to Current Therapeutic Drug Monitoring: Adapting to the Era of Individualized Therapy. Pharmacotherapy, 2021, 41, 953-963.	2.6	2
11	Bacterial Mixology: Combining Pharmacodynamic Models to Predict In Vitro Competition of MCR-1-Harboring E. coli. Antibiotics, 2022, 11, 34.	3.7	1
12	1325. Things that go Bump in the Night: Combating Klebsiella pneumoniae co-producing New Delhi metallo-beta-lactamase (NDM) and Mobile Colistin Resistance (MCR). Open Forum Infectious Diseases, 2020, 7, S673-S673.	0.9	0